We have a robust clinical and translational science research program with a primary mission of the advancement and treatment of Pulmonary Hypertension.
In addition, we are the only designated Pulmonary Hypertension Comprehensive Care Center (PHCCC) in the state of Kansas and the region.
We are dedicated to enhancing a better understanding of pulmonary hypertension and finding novel and more efficient ways to treat patients with this life-altering disease.
We are dedicated to advancing treatment and therapies available to individuals with an active COVID-19 infection.
We are the only outpatient COVID-positive research center in the state of Kansas and in the region.
KUMC is also focused on expanding upon research and developing new treatments and testing for individuals that are recovering from COVID-19, are recovered from COVID-19, and have long term post-COVID-19 symptoms (“long haul”).
We are highly active in outcomes research and research into the delivery of evidence-based care.
Specific areas of interest include outcomes of sepsis treatment in rural settings, determinants of outcome in the quarternary medical center, use of electronic early warning systems for sepsis diagnosis, and outcomes in patients with specific conditions, such as hematological malignancies and pulmonary hypertension.
We have also worked with members of the School of Engineering at Kansas State University to develop agent-based models of innate immunity in sepsis.
Our research focuses on understanding what causes morbidity from asthma and COPD and how to best prevent or treat these common chronic conditions.
Dr. Mario Castro, MD, MPH, Division Chief of Pulmonary, Critical Care and Sleep Medicine, Vice Chair for Clinical and Translational Research, Director of the Rainbow Clinical and Translational Science Unit (CTSU, Frontiers), leads the AATRU group, which currently has more than 25 ongoing studies, all of which have opportunities for students, residents, felows and junior faculty to perform focused research in an area of interest.